JP2012527475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012527475A5 JP2012527475A5 JP2012512030A JP2012512030A JP2012527475A5 JP 2012527475 A5 JP2012527475 A5 JP 2012527475A5 JP 2012512030 A JP2012512030 A JP 2012512030A JP 2012512030 A JP2012512030 A JP 2012512030A JP 2012527475 A5 JP2012527475 A5 JP 2012527475A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- uric acid
- compound
- viii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 16
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 12
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 12
- 229940116269 uric acid Drugs 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 201000005569 Gout Diseases 0.000 claims 8
- 210000001519 tissue Anatomy 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 210000000056 organ Anatomy 0.000 claims 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 4
- 229960003459 allopurinol Drugs 0.000 claims 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 229960005101 febuxostat Drugs 0.000 claims 3
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 2
- 101800000414 Corticotropin Proteins 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 201000001431 Hyperuricemia Diseases 0.000 claims 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 229960001338 colchicine Drugs 0.000 claims 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 2
- 229960000258 corticotropin Drugs 0.000 claims 2
- 230000029142 excretion Effects 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims 2
- 229960003081 probenecid Drugs 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 229960003329 sulfinpyrazone Drugs 0.000 claims 2
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 1
- 206010007027 Calculus urinary Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102100039259 Cytochrome c oxidase subunit 8A, mitochondrial Human genes 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 101000745956 Homo sapiens Cytochrome c oxidase subunit 8A, mitochondrial Proteins 0.000 claims 1
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 claims 1
- 206010027439 Metal poisoning Diseases 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- -1 aromatic ring compound Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000007211 cardiovascular event Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000008127 lead poisoning Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 238000012261 overproduction Methods 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 239000000651 prodrug Chemical group 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 208000008281 urolithiasis Diseases 0.000 claims 1
- 0 CC1=C(*C=C)[C@@](*)*C=C1* Chemical compound CC1=C(*C=C)[C@@](*)*C=C1* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18010209P | 2009-05-20 | 2009-05-20 | |
| US61/180,102 | 2009-05-20 | ||
| PCT/US2010/035573 WO2010135530A2 (en) | 2009-05-20 | 2010-05-20 | Compounds, compositions and methods for modulating uric acid levels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012527475A JP2012527475A (ja) | 2012-11-08 |
| JP2012527475A5 true JP2012527475A5 (https=) | 2013-02-21 |
Family
ID=43126769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012512030A Withdrawn JP2012527475A (ja) | 2009-05-20 | 2010-05-20 | 尿酸値を調節するための化合物、組成物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120122780A1 (https=) |
| EP (1) | EP2432774A4 (https=) |
| JP (1) | JP2012527475A (https=) |
| CA (1) | CA2761335A1 (https=) |
| WO (1) | WO2010135530A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2736117C (en) | 2008-09-04 | 2013-11-19 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| US8242154B2 (en) | 2008-09-04 | 2012-08-14 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| EP2560642A4 (en) | 2010-03-30 | 2013-12-18 | Ardea Biosciences Inc | TREATMENT OF GICHT |
| EP2582683B1 (en) * | 2010-06-15 | 2018-03-21 | Ardea Biosciences, Inc. | Treatment of gout and hyperuricemia |
| BR112012032193A2 (pt) | 2010-06-16 | 2019-09-24 | Ardea Biosciences Inc | composto, composiçoes e métodos de uso de feniltioacetato |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| JP5363636B2 (ja) * | 2011-10-21 | 2013-12-11 | ファイザー・リミテッド | 新規な塩および医学的使用 |
| EP3501520A1 (en) | 2011-11-03 | 2019-06-26 | Ardea Biosciences, Inc. | 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same |
| CN104262276B (zh) * | 2014-10-07 | 2016-06-22 | 张远强 | 含卤代苯的四氮唑乙酸类化合物、其制备方法及用途 |
| CN104341363B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
| CN104326993B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
| CN104370842B (zh) * | 2014-10-27 | 2016-07-13 | 张远强 | 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
| CN104326998B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途 |
| CN104327000B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
| CN104341362B (zh) * | 2014-10-27 | 2016-07-13 | 张远强 | 三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
| CN104370841B (zh) * | 2014-10-27 | 2016-07-13 | 张远强 | 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
| ES2865182T3 (es) * | 2014-12-29 | 2021-10-15 | Nippon Chemiphar Co | Inhibidor de URAT1 |
| CN104817509B (zh) * | 2015-04-13 | 2019-05-17 | 安徽省逸欣铭医药科技有限公司 | Lesinurad类似物及其制备方法和医药用途 |
| CN106187926B (zh) * | 2015-04-30 | 2018-11-27 | 天津药物研究院有限公司 | 含二芳基甲烷结构的羧酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途 |
| JP7301042B2 (ja) | 2018-03-30 | 2023-06-30 | 住友化学株式会社 | 複素環化合物及びそれを含有する有害節足動物防除組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63152367A (ja) * | 1986-08-25 | 1988-06-24 | Shionogi & Co Ltd | ３―パーフルオロアルキル―５―置換オキシイソオキサゾール誘導体およびそれを有効成分として含有する除草剤 |
| EP1723123A4 (en) * | 2004-03-08 | 2009-12-02 | Wyeth Corp | ION CHANNEL MODULATORS |
| US7157998B2 (en) * | 2004-04-09 | 2007-01-02 | Matsushita Toshiba Picture Display Co., Ltd. | Ferrite core, deflection yoke, and color picture tube apparatus |
| EP1783124A4 (en) * | 2004-08-27 | 2009-07-08 | Astellas Pharma Inc | 2-PHENYLTHIOPHENDERIVAT |
| WO2008118626A2 (en) * | 2007-03-08 | 2008-10-02 | Burnham Institute For Medical Research | Inhibitors of jnk and methods for identifying inhibitors of jnk |
| ME01294B (me) * | 2007-11-27 | 2013-06-20 | Ardea Biosciences Inc | Nova jedinjenja i kompozicije i metode upotrebe |
| EP2432468A2 (en) * | 2009-05-20 | 2012-03-28 | Ardea Biosciences, Inc. | Methods of modulating uric acid levels |
-
2010
- 2010-05-20 EP EP10778383A patent/EP2432774A4/en not_active Withdrawn
- 2010-05-20 JP JP2012512030A patent/JP2012527475A/ja not_active Withdrawn
- 2010-05-20 WO PCT/US2010/035573 patent/WO2010135530A2/en not_active Ceased
- 2010-05-20 US US13/321,155 patent/US20120122780A1/en not_active Abandoned
- 2010-05-20 CA CA2761335A patent/CA2761335A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012527475A5 (https=) | ||
| US6803380B1 (en) | 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them | |
| JP2017524704A5 (https=) | ||
| ES2314132T3 (es) | Pirrolopirimidinas como inhibidores vii de la fosfodiesterasa. | |
| TWI772309B (zh) | 化合物及其於降低尿酸位準之用途(二) | |
| ES2532210T3 (es) | Métodos para el tratamiento concomitante de teofilina y febuxostat | |
| US9428542B2 (en) | Lupane triterpenoid derivatives and pharmaceutical use thereof | |
| JP2013528655A5 (https=) | ||
| US20100292274A1 (en) | Haloalkyl heteroaryl benzamide compounds | |
| EA010835B1 (ru) | Лекарственное средство для лечения рака | |
| JP2008510828A5 (https=) | ||
| RU2018120242A (ru) | Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов | |
| JP2011504935A5 (https=) | ||
| RU2006105804A (ru) | Нитрооксипроизводные лозартана, валсартана, кандесартана, телмисартана, эпросартана и олмесартана в качестве блокаторов рецепторов ангиотензина ii для лечения сердечно-сосудистых заболеваний | |
| JP2006143737A5 (https=) | ||
| WO2014119681A1 (ja) | アゾールベンゼン誘導体 | |
| JP2014532726A5 (https=) | ||
| JP6134072B2 (ja) | キサンチンオキシダーゼ阻害薬 | |
| US10093631B2 (en) | Bifunctional compounds and use for reducing uric acid levels | |
| RU2004138552A (ru) | Нитрооксипроизводные ингибиторов циклооксигеназы-2 | |
| JP2020524178A (ja) | ファルネソイドｘ受容体および可溶性エポキシドヒドロラーゼの二重調節剤 | |
| CA2626402A1 (en) | Potassium channel inhibitors | |
| JP2004521150A5 (https=) | ||
| EP2113502B1 (fr) | Composés de type hydrazide et leur utilisation dans des compositions pharmaceutiques pour le traitement des maladies cardiovasculaires | |
| RU2004125609A (ru) | Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2 |